Current Takeaway
Autonomic nervous system dysfunction (dysautonomia), particularly manifesting as postural orthostatic tachycardia syndrome (POTS) and orthostatic intolerance (OI), is a central biological feature of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long COVID. In these conditions, upright posture or metabolic stress triggers cardiorespiratory and cerebrovascular instability, causing symptoms such as severe lightheadedness, heart rate spikes, blood pressure fluctuations, cognitive impairment (“brain fog”), and post-exertional malaise. Emerging evidence demonstrates that these symptoms are driven by quantifiable physiological impairments, including reduced cerebral blood flow, peripheral small fiber neuropathy (SFN), and preload failure, which is the inadequate return of blood to the heart during exertion.
Recent clinical comparisons and large-scale reviews confirm that ME/CFS and Long COVID share a near-identical autonomic phenotype. High-throughput diagnostics, transcutaneous Doppler, and head-up tilt testing show that over 89% of patients in both groups experience impaired cerebral autoregulation and hemodynamic failure. Additionally, empirical cytokine profiling demonstrates that pre-COVID POTS and Long COVID-associated POTS exhibit indistinguishable circulating inflammatory cytokine profiles, reinforcing that post-viral dysautonomia shares a common immune-mediated substrate with pre-pandemic POTS. However, physiological differences under specific metabolic stressors—such as distinct cerebrovascular resistance changes under hypercapnia in ME/CFS versus oxygenation deficits under head-up tilt in Long COVID—indicate that different underlying pathways might drive these similar symptoms. Additionally, new neuroimaging suggests that neuroinflammation localized in the brainstem’s dorsolateral medulla may act as a central driver of these autonomic and cognitive symptoms by disrupting the brain-immune axis. Recent validation of the 10-minute NASA Lean Test in chronic post-COVID cohorts confirms its utility as an accessible clinical screening tool, though it reveals a significant dissociation where 83% of hemodynamically negative patients still report severe orthostatic symptoms. Furthermore, long-term post-COVID ocular symptoms have been linked to corneal small-fiber neuropathy and pupillary autonomic dysfunction, with new diagnostic models developed using ophthalmic tools and tear-fluid proteins; however, these ocular findings are specific to post-COVID cohorts and have not been validated in general ME/CFS populations.
Although the physical basis of dysautonomia in post-infectious syndromes is increasingly established, significant uncertainties remain. Current therapeutic interventions, including compression garments, ivabradine, and beta-blockers, are supported only by low-certainty evidence, and no clinical trials have evaluated these treatments specifically within the comorbid ME/CFS population. This represents a critical knowledge gap, particularly because standard POTS recommendations like progressive physical training can cause severe post-exertional crashes in ME/CFS patients due to post-exertional malaise. Further research is required to determine the molecular triggers of post-infectious dysautonomia, standardize functional vascular diagnostics, and validate targeted immunomodulatory and hemodynamic therapies in well-stratified clinical cohorts.
Why This Matters
Understanding autonomic dysfunction and POTS is essential for establishing objective, measurable markers of disease severity in post-infectious syndromes. By identifying physical pathology such as preload failure, reduced cerebral blood flow, and small fiber neuropathy, this research shifts the clinical understanding of ME/CFS and Long COVID from subjective symptom checklists to objective, quantifiable vascular and neurological deficits. Pinpointing downstream mechanisms, such as impaired cerebrovascular autoregulation or brainstem neuroinflammation, provides clear pathways for therapeutic development and drug repurposing. Furthermore, demonstrating the high prevalence of orthostatic intolerance and the potential harm of standard POTS exercise protocols in patients with post-exertional malaise directly shapes clinical guidelines, emphasizing the need for pacing-aware, individualized care models.
State of Evidence
- Established: Postural orthostatic tachycardia syndrome (POTS) and orthostatic intolerance (OI) are highly prevalent in ME/CFS and Long COVID, affecting the vast majority of patients. Cerebral blood flow is significantly reduced during orthostatic challenges in these cohorts compared to healthy controls, and comorbid ME/CFS and orthostatic intolerance leads to cumulative deficits in cerebral perfusion. Autonomic symptom burden directly correlates with overall clinical severity, functional impairment, fatigue, and pain.
- Plausible but early: ME/CFS and Long COVID share a near-identical autonomic phenotype characterized by preload failure during exercise, small fiber neuropathy, and reduced cerebral blood flow. Sensory small fiber neuropathy (SFN) in these populations is non-length-dependent and patchy, indicating widespread peripheral nerve damage rather than typical distal-to-proximal degeneration. Pre-COVID POTS and Long COVID-associated POTS share indistinguishable circulating inflammatory cytokine profiles, pointing toward a common neuroinflammatory and immune-mediated substrate across post-viral and non-viral dysautonomia. Autonomic dysfunction can be directly triggered by acute bacterial infections (such as Coxiella burnetii in Q fever), leading to immediate impairment of parasympathetic regulation and baroreflex control. Advanced neuroimaging (7T MRI) reveals localized neuroinflammation in the brainstem’s dorsolateral medulla, which may serve as the central driver for autonomic and cognitive symptoms. Under metabolic stressors like hypercapnia, ME/CFS and Long COVID exhibit distinct cerebrovascular autoregulation and peripheral oxygenation profiles. In post-COVID syndrome, the 10-minute NASA Lean Test is an effective screening tool for POTS, although subjective orthostatic symptoms often dissociate from objective hemodynamic thresholds. Persistent post-COVID ocular symptoms are linked to localized corneal small-fiber neuropathy, local immune dysregulation, and impaired pupillary autonomic control (with diagnostic models developed using clinical ophthalmic tools or tear proteins). Non-tachycardic mechanisms—including reduced left ventricular chamber dimensions (small heart syndrome), paradoxically downregulated renin-angiotensin-aldosterone and antidiuretic hormone (ADH) signaling, and central vestibular disequilibrium—are proposed contributors to orthostatic intolerance beyond standard heart-rate criteria, based on single-clinic observational evidence.
- Not established: Standardized, universally accepted biomarkers that distinguish post-infectious dysautonomia from other forms of primary POTS. The long-term efficacy and safety of pharmacotherapies (such as ivabradine, beta-blockers, midodrine, or pyridostigmine) specifically in patients with comorbid ME/CFS and POTS.
- Key limitations: Most treatment studies for POTS are small, have a high risk of bias, and completely exclude or fail to stratify patients with comorbid ME/CFS. Severely ill, bedbound patients are underrepresented in hemodynamic and tilt-table research due to their inability to tolerate orthostatic challenges. Methodological differences in measuring cerebral blood flow (TCD, MRI, SPECT) prevent direct meta-analysis of perfusion deficits. Current studies frequently rely on self-reported questionnaires or subjective autonomic symptom scores rather than standardized functional and objective testing. Cross-sectional cytokine profiling studies cannot determine whether inflammatory marker elevations cause autonomic dysregulation or result secondary to vascular impairment. The diagnostic models for post-COVID ocular autonomic dysfunction require specialized instruments (like corneal confocal microscopy) or tear-fluid assays that are not widely accessible, and these findings have not been evaluated in non-COVID ME/CFS cohorts. Additionally, the utility and diagnostic thresholds of the NASA Lean Test require further longitudinal validation in broader, non-COVID ME/CFS populations. Protocol selection between active standing, passive standing, and tilt-table testing materially influences which physiological deficits and patient subsets are identified, and diagnostic thresholds for pediatric PoTS remain unsettled.
Timeline
2023-11-15 - Comparative study characterizes dysautonomia and small fiber neuropathy in ME/CFS and post-COVID
A comparative clinical study demonstrated that both ME/CFS and post-COVID patients share significant, measurable features of dysautonomia and sensory small fiber neuropathy (SFN). The researchers found that rest and standing heart rates were significantly elevated in both cohorts compared to controls, with POTS confirmed in 31% of the ME/CFS group and 13.8% of the post-COVID group. Furthermore, delayed sensory nerve responses to heat stimuli indicated damage to unmyelinated C-type fibers, and sweat gland function tests showed a patchy, non-length-dependent pattern of neuropathy. This provides objective physiological evidence that validates common patient symptoms and suggests a shared mechanism of peripheral nerve damage. However, the study’s small, unequal sample sizes and gender imbalances across cohorts limit the generalizability of these findings, and the results do not prove a direct causal link between SFN and clinical fatigue severity.
Sources:
2025-08-26 - Systematic review establishes cumulative cerebral hypoperfusion in comorbid ME/CFS and orthostatic intolerance
A systematic review analyzing 118 studies with over 9,000 participants established that reduced cerebral blood flow (CBF) is a consistent physiological abnormality in both ME/CFS and orthostatic intolerance. Crucially, the review found that patients with comorbid ME/CFS and orthostatic intolerance experience a significantly greater decrease in brain blood flow than those with ME/CFS alone. This provides a clear, objective explanation for orthostatic symptoms and cognitive impairment (“brain fog”) under hemodynamic stress. The consolidated data support using cerebral blood flow monitoring as a key biomarker for disease severity. However, the high variability in measurement methods across the included studies prevented a formal meta-analysis, and severely ill, bedbound patients were underrepresented because they are often unable to tolerate orthostatic challenge tests.
Sources:
2025-09-05 - Multi-site clinical assessment confirms autonomic symptom burden scales with ME/CFS severity
A large-scale, multi-site clinical study of 301 ME/CFS patients and 141 controls confirmed that autonomic symptoms are nearly universal in ME/CFS, affecting 97% of patients. Using the COMPASS-31 questionnaire and the NASA Lean Test, researchers demonstrated that the severity of orthostatic, gastrointestinal, and pupillomotor symptoms directly correlates with the severity of fatigue, pain, sleep disruption, and physical impairment. This validates dysautonomia as a core component of the disease rather than a secondary complication. The findings underscore the clinical necessity of routine autonomic screening in patient care to identify targetable symptoms. However, the study cohort was predominantly white, highly educated, and insured, which may limit how well these findings represent the broader, more diverse ME/CFS population.
Sources:
2025-10-14 - Pilot study identifies distinct cerebrovascular and peripheral oxygenation responses under stress
A physiological pilot study comparing 12 ME/CFS patients, 9 Long COVID patients, and 10 healthy controls revealed distinct vascular phenotypes under metabolic and orthostatic stress. When exposed to high carbon dioxide levels (hypercapnia), ME/CFS patients demonstrated a significantly greater reduction in cerebrovascular resistance and impaired cerebral autoregulation, which correlated directly with impaired cognitive-motor integration. In contrast, Long COVID patients during a head-up tilt test exhibited lower peripheral and end-tidal oxygen levels along with reduced parasympathetic vagal withdrawal. This suggests that distinct physiological mechanisms may drive the shared symptoms of fatigue and brain fog in these two patient groups. However, these findings are preliminary due to the small sample size and do not rule out the influence of illness duration or specific viral variants.
Sources:
2025-11-12 - Systematic review highlights low-certainty evidence and lack of trials for ME/CFS-comorbid POTS
A systematic review of 45 POTS treatment studies highlighted a significant lack of high-quality evidence, with the certainty of evidence for most interventions rated as low or very low. The review found that non-pharmacological options like compression garments and salt supplementation, along with drugs like ivabradine and beta-blockers, show some efficacy in general POTS cohorts. Most critically, the authors identified a complete absence of clinical trials specifically evaluating POTS therapies in patients with comorbid ME/CFS. This highlights the risk of applying standard POTS recommendations, such as progressive physical exercise, which can cause severe crashes in ME/CFS patients due to post-exertional malaise. However, the review is limited by the small sample sizes and high risk of bias in the analyzed studies, and it does not establish new treatment protocols.
Sources:
2025-12-19 - Clinical study links acute Coxiella burnetii infection to immediate baroreflex and parasympathetic impairment
A clinical study of 100 Q fever patients and 56 controls demonstrated that acute infection with the bacterium Coxiella burnetii is directly associated with significant autonomic nervous system impairment. Standard cardiovascular reflex testing and tilt-table assessments revealed reduced parasympathetic regulation, baroreflex dysfunction, and high rates of orthostatic syncope in the infected cohort. This provides objective evidence that post-infectious dysautonomia can develop shortly after an acute bacterial trigger, mirroring post-viral pathways. The study highlights the utility of short-term cardiovascular testing in detecting early post-infectious autonomic changes. However, the cross-sectional design of the study cannot prove that the infection caused long-term autonomic chronic illness, and longitudinal follow-ups are needed to track symptom progression.
Sources:
2026-01-09 - Clinical review outlines multi-system nature of POTS and calls for multidisciplinary care models
A comprehensive expert review synthesized the current clinical understanding of POTS, emphasizing that it is a complex, multi-system autonomic disorder rather than an isolated cardiovascular condition. The authors detailed how POTS involves autoimmune, hyperadrenergic, neuropathic, and post-viral mechanisms, requiring a combination of lifestyle adjustments and pharmacological agents like ivabradine. This consensus highlights the need for multidisciplinary clinical teams, including primary care and specialists, to manage the broad symptom burden. The publication underscores the significant diagnostic delays and lack of trained specialists in autonomic medicine worldwide. However, the review is a narrative consensus of literature and does not present new primary clinical trial data or establish superior treatment efficacy for specific subtypes.
Sources:
2026-01-23 - Comparative analysis demonstrates a shared autonomic phenotype of preload failure, SFN, and cerebral hypoperfusion
A retrospective study comparing 143 Long COVID patients and 170 ME/CFS patients confirmed that the two conditions share a near-identical physiological autonomic phenotype. The researchers found reduced cerebral blood flow in approximately 90% of both groups, widespread autonomic failure in over 89%, small fiber neuropathy in a majority, and preload failure during exercise in over 92% of patients. This provides strong physiological evidence supporting the hypothesis that Long COVID and ME/CFS exist on the same disease spectrum. The findings indicate that standard blood panels cannot distinguish the conditions, necessitating functional autonomic and exercise testing. However, the retrospective design limits the ability to track the onset of these changes, and the study does not identify the primary molecular triggers driving the vascular and nerve damage.
Sources:
2026-02-02 - Clinical review proposes neuroimmune framework linking POTS to brainstem neuroinflammation
A narrative review established a unified neuroimmune framework for POTS, ME/CFS, and Long COVID, linking autonomic symptoms directly to central neuroinflammation and autoimmunity. Synthesizing neuroimaging and immunological studies, the authors highlighted the presence of G-protein coupled receptor (GPCR) autoantibodies, mitochondrial dysfunction, and cerebral hypoperfusion across all three conditions. Crucially, the review pointed to 7T MRI evidence of localized neuroinflammation in the brainstem’s dorsolateral medulla, which regulates cardiorespiratory and autonomic function. This shifts the clinical focus from peripheral cardiovascular symptoms to central neuroimmune drivers, supporting the investigation of immunomodulating therapies. However, this is a conceptual synthesis rather than a primary empirical study, and the presence of brainstem neuroinflammation requires validation in larger, replicated patient cohorts.
Sources:
2026-04-28 - Structural equation modeling validates distinct neuroimmune and autonomic symptom clusters
A translational modeling study of 748 ME/CFS patients validated that patient symptoms are organized into statistically coherent biological clusters rather than being random. Using factor analysis and structural equation modeling (SEM), the researchers confirmed distinct and highly consistent clusters representing brain symptoms (fog, hypersensitivity, headache), gastrointestinal symptoms, immunological dysfunction, and a higher-order vegetative (autonomic) symptom complex. This provides a robust statistical framework for patient stratification, showing that patient-reported symptoms reflect distinct, underlying pathophysiological pathways. However, the study inferred these biological mechanisms from literature integration rather than direct laboratory measurements in the participants, and the cohort was subject to potential self-selection bias.
Sources:
2026-05-29 - Study identifies monocyte oxidative stress and IsoLG neoantigens as drivers of Long COVID POTS
A case-control study by Abd-Eldayem et al. released as a preprint linked monocyte oxidative stress to persistent immune activation in Long COVID Postural Orthostatic Tachycardia Syndrome (LCPOTS). Comparing 25 LCPOTS patients with 15 controls who recovered from COVID-19 without POTS, researchers found that LCPOTS monocytes exhibit increased mitochondrial content, elevated superoxide production, and downregulated NRF2-dependent antioxidant enzymes. This oxidative state leads to increased formation of isolevuglandin (IsoLG) neoantigens, which modify self-proteins to activate T cells. Consequently, LCPOTS patients showed a 3-fold increase in circulating T cell-monocyte doublets forming immunological synapses, which correlated with autonomic symptom severity. As a preprint, this work has not yet undergone peer review. Furthermore, the cohort size is small and the design is observational, meaning it cannot prove a causal relationship between monocyte oxidative stress and cardiovagal dysfunction.
Sources:
2026-07-02 - Study validates NASA Lean Test for POTS screening in chronic post-COVID
A cross-sectional study of 221 patients with chronic post-COVID syndrome (PCS) undergoing inpatient rehabilitation evaluated the diagnostic utility of the 10-minute NASA Lean Test (NLT). The researchers found that 16.7% of the cohort met the hemodynamic criteria for postural orthostatic tachycardia syndrome (POTS). Crucially, 83% of the patients who did not meet the objective POTS criteria still reported significant orthostatic symptoms during the test, highlighting a clear dissociation between subjective symptoms and objective hemodynamic thresholds. The findings support using the NLT as an accessible, in-office clinical screening tool to help identify orthostatic intolerance in post-viral patients. However, the study is limited by its reliance on a single screening session and its cohort from a single rehabilitation clinic, which introduces potential selection bias. Furthermore, because standing can trigger severe orthostatic symptoms or syncope, the test requires clinical supervision and safety protocols.
Sources:
2026-07-08 - Study links post-COVID ocular symptoms to corneal small-fiber neuropathy and dysautonomia
A study in Nature Communications identified that long-term ocular symptoms (including eye pain, photophobia, and focusing difficulties) after mild COVID-19 are driven by an ocular syndrome involving corneal small-fiber neuropathy, immune dysregulation, and autonomic dysfunction. The researchers demonstrated that damage to the nerves regulating pupillary autonomic control and eye muscle coordination leads to these persistent symptoms, sometimes resulting in adult-onset strabismus. To facilitate clinical detection, the authors developed two diagnostic models: one using standard ophthalmic clinic instruments and a second that incorporates specific tear-fluid proteins to improve diagnostic accuracy. This provides a biological explanation and objective diagnostic pathways for post-viral eye complaints that often appear normal on standard optometric exams. However, the tear-fluid protein model and corneal confocal microscopy require specialized equipment not widely available in primary care, and both diagnostic models require validation in larger, independent, and geographically diverse cohorts.
Sources:
2026-07-21 - POTS study points toward inflammatory cytokines; pre-COVID and Long COVID POTS indistinguishable
An empirical study published in MDPI Biomedicines analyzed circulating inflammatory cytokine profiles in patients with Postural Orthostatic Tachycardia Syndrome (POTS), comparing pre-COVID POTS cohorts with Long COVID-associated POTS. The researchers found that circulating cytokine abnormalities in pre-COVID POTS and Long COVID POTS were statistically indistinguishable, showing shared elevations in key pro-inflammatory mediators. This indicates a common neuroinflammatory and immune-mediated pathophysiology driving dysautonomia across both post-viral and non-viral POTS etiologies. For patients, these findings validate that post-COVID POTS shares the same underlying inflammatory substrate as pre-pandemic POTS, supporting unified diagnostic and management approaches. However, the study’s cross-sectional design cannot establish whether cytokine elevations are causative drivers of autonomic dysregulation or secondary consequences of cardiovagal and vascular dysregulation.
Sources:
2026-07-28 - Case-control study finds PoTS in 39% of adolescents with ME/CFS
A peer-reviewed case-control study evaluated orthostatic intolerance (OI) and diagnostic criteria for postural orthostatic tachycardia syndrome (PoTS) in 18 adolescents with ME/CFS compared to 18 matched healthy controls. During a 10-minute passive standing test (PST), expert-confirmed PoTS was identified in 39% of the adolescent ME/CFS group (0% in controls), while a clinical history of OI was present in 83% of patients (versus 17% in controls). The authors demonstrated that absolute upright heart rate thresholds were superior to standard relative heart rate increments (+40 bpm) for diagnosing pediatric PoTS, proposing a practice-level rule combining a positive OI history with at least 60% of upright readings exceeding pediatric normative limits. However, the study is constrained by a small, single-center sample size and evaluated a single 10-minute test without longitudinal follow-up, and the proposed 60% absolute threshold rule requires external replication before clinical adoption. Because 10 minutes of upright standing can trigger presyncope, syncope, or severe post-exertional symptom exacerbation, the protocol requires close clinical supervision and is not feasible for bedbound or severely affected pediatric patients unable to stand.
Sources:
2026-07-29 - Clinical update proposes vestibular disequilibrium alongside small heart syndrome as drivers of orthostatic intolerance
A clinical review and mechanistic update synthesized cardiovascular, neurohumoral, and vestibular contributors to orthostatic intolerance in ME/CFS cohorts. The author reviewed echocardiographic and radiographic evidence for “small heart syndrome” (cardiothoracic ratio ≤42% and reduced left ventricular dimension), showing that diminished stroke volume contributes to upright low-output circulatory states and cerebral hypoperfusion. The paper highlighted paradoxical downregulation of the renin-angiotensin-aldosterone and antidiuretic hormone (ADH/vasopressin) systems despite hypovolemia, pointing to neurohumoral uncoupling in blood volume regulation. Furthermore, the synthesis proposed central vestibular disequilibrium as an overlooked non-cardiovascular driver of orthostatic disability, noting that in 160 ME/CFS patients, 45% displayed static or kinetic balance instability and 10-minute active standing test failure occurred exclusively in those with disequilibrium. However, the evidence rests primarily on narrative literature synthesis and retrospective single-clinic observational data without randomized control arms, and active standing tests exclude severely affected, bedbound patients. Mentioned therapeutic approaches like desmopressin and repetitive transcranial magnetic stimulation (rTMS) remain preliminary and investigational; desmopressin in particular carries a serious risk of severe hyponatremia and must not be used without strict baseline sodium monitoring and clinical oversight.
Sources:
Open Questions
- What specific molecular mechanisms link post-infectious immune activation or autoantibodies to the development of non-length-dependent small fiber neuropathy?
- How does localized brainstem neuroinflammation, particularly in the dorsolateral medulla, disrupt central baroreflex control and sympathovagal balance?
- What are the primary physiological drivers of preload failure in post-infectious cohorts, and how do they relate to endothelial dysfunction, microclots, and blood volume depletion?
- Which clinical biomarkers or functional tests can reliably predict whether a patient with comorbid ME/CFS and POTS will benefit from ivabradine, beta-blockers, or volume expansion therapies without triggering post-exertional malaise?
- What explaining factors cause ME/CFS and Long COVID patients to exhibit distinct cerebrovascular and peripheral oxygenation responses under specific stress challenges despite showing near-identical resting autonomic function?